Dec. 2, 2005 -- The US Food and Drug Administration (FDA), Amgen Inc, and Ortho Biotech Clinical Affairs, LLC, have notified healthcare professionals via letter regarding revisions to the safety ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Results of a 24-week trial that compared ...

Hospira Inc. presented two studies that demonstrate the pharmacokinetic and pharmacodynamic equivalence of its proposed biosimilar Epoetin Hospira. The U.S. Food and Drug Administration has ...

Erythropoietin (EPO) is primarily known to many as a hormone for blood formation. However, it has been known for some years ...

September 26, 2008 — Use of high-dose epoetin alfa (Epogen, Amgen, Inc; Procrit, Ortho Biotech) in acute ischemic stroke patients has been linked to an increased risk for death, the US Food and Drug ...

The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, ...

Pune, Maharashtra, India, January 18 2021 (Wiredrelease) MarketResearch.Biz –:An extensive and elaborate primary research on Global Erythropoietin (EPO) Drugs Market report sheds light on numerous ...

hip fracture_TS_502550326 Higher erythropoietin doses may be an independent risk factor for hip fractures in hemodialysis patients, data suggest. Higher erythropoietin (EPO) doses are associated with ...

High-dose erythropoietin (Epo) is a promising neuroprotective treatment in neonates with hypoxic–ischemic encephalopathy (HIE) receiving hypothermia. We evaluated the pharmacokinetics and ...